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1. Introduction 
1.1. Overview 
Transcatheter aortic valve implantation (TAVI) has become the standard therapy for 
symptomatic severe aortic stenosis (AS) in elderly patients (> 75 years), especially if 
transfemoral access is possible (TF-TAVI). These patients commonly present with 
comorbidities and a substantial proportion of them has an impaired left ventricular ejection 
fraction (LVEF).  
It is controversial whether an impaired LVEF per se increases the risk of mortality after 
TAVI. The results of observational studies are conflicting and the cutoff points for LVEF 
that are associated with an increased risk vary markedly between different studies.  
Moreover, impaired LVEF may result in a low flow state producing a low pressure gradient 
across the stenotic aortic valve despite the presence of a severe AS (aortic valve area < 1.0 
cm2 and mean transvalvular aortic gradient < 40 mmHg). This condition is known as low 
gradient aortic stenosis (LGAS) and was classically described in patients with an impaired 
LVEF, but is also paradoxically seen in elderly patients with a normal LVEF. Patients with 
LGAS are deemed at increased risk of adverse outcome after TAVI.  
The American Society of Echocardiography (ASE) and the European Association of 
Cardiovascular Imaging (EACVI) recommended new cutoff values for a normal, mildly 
abnormal, moderately abnormal and severely abnormal LVEF. The impact of this 
categorization on the outcome after TAVI has not been previously tested.   
We aimed to assess the impact of the ASE/EACVI classification of LVEF on 30-day and 1-
year mortality after TF-TAVI and to evaluate if the presence of LGAS in patients with an 
impaired LVEF is associated with a worse outcome. 
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1.2. Degenerative aortic valve stenosis 
1.2.1. Epidemiology and pathogenesis 
Degenerative AS is the most common valvular heart disease in developed countries. With 
increasing life expectancy of the general population, more patients with degenerative AS are 
expected to be seen in the Western world (Freeman and Otto 2005, Otto 2006). In a previous 
report from Norway, AS can affect up to 9.8% of people ≥ 80 years with an overall 
prevalence of 2.8% in patients > 75 years of age (Eveborn et al. 2013).  
AS is an active disease characterized by lipid accumulation, inflammation, and calcification. 
Many believe that AS is not a disease of the aortic valve only but rather of the entire vascular 
system including the left ventricle and systemic vasculature (Otto 2006). Additionally, AS 
is a progressive disease that carries a high mortality within a few years, if left untreated once 
symptoms occur. When severe AS is present, the rate of progression to symptoms is high, 
with an event-free survival of only 30% to 50% at two-years. Progression of AS can be more 
rapid in older patients and in those with more severe leaflet calcification (Nishimura et al. 
2014). 
1.2.2. Assessment and grading of severity 
The classical symptoms of a severe AS are angina pectoris, dyspnea and syncope. A loud 
systolic ejection murmur over the right upper sternal border detected by auscultation with 
late peaking and radiation to the carotids is usually the first clinical clue for diagnosis of 
severe AS (Vahanian et al. 2012).  
Historically, diagnosis of severe AS was made invasively through cardiac catheterization 
and determination of the aortic valve area using the Gorlin formula. At present, this has been 
replaced by transthoracic echocardiography (TTE) which plays a crucial role not only in 
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diagnosis, but also in the proper patient selection prior to valve replacement (Popovic et al. 
1997, Carabello 2013, Rashedi and Otto 2015).  
Two-dimensional TTE allows the proper assessment of valve morphology, leaflets’ 
excursion, calcification (presence and extent), and determines the degree of left ventricular 
hypertophy, left ventricular systolic function and left atrial enlargement. TTE allows 
additionally the grading of the severity of AS based on the Doppler assessment of the peak 
velocity across the aortic valve, on the mean transvalvular aortic gradient and on the 
calculation of the aortic valve area. The peak jet velocity is measured from multiple views 
(apical, right parasternal, suprasternal) to detect the highest velocity. The mean transvalvular 
pressure gradient is estimated from the jet flow profile by applying the simplified Bernoulli 
equation. It estimates the average gradient across the valve throughout the entire systole. The 
aortic valve area is calculated using the continuity equation and has the advantage of being 
more accurate, unlike the above mentioned two parameters, in  patients with a very low or a 
very high flow rate (Holmes et al. 2012). Both the left ventricular outflow diameter and 
velocity must be measured for calculation of the aortic valve area (Baumgartner et al. 2009, 
Vahanian et al. 2012). Indexing of the aortic valve area to the body surface area may be 
helpful to diagnose severe AS in patients with a very small body size. Grading of the severity 
of AS based on these parameters is shown in table 1 [modified from (Lindman et al. 2016)]. 
Table 1: Assessment of the severity of aortic stenosis 
 Mild Moderate Severe 
Peak jet velocity (m/s) 2 - 3 3 - 4 ≥ 4 
Mean transvalvular aortic gradient (mmHg) 10 - 19 20 - 39 ≥ 40 
Aortic valve area (cm2) 1.6 – 2.0 > 1 – 1.5 ≤ 1.0 
Indexed aortic valve area (cm2/m2) > 0.9 > 0.6 – 0.9 ≤ 0.6 
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Transoesophageal echocardiography may be used if the quality of the TTE image is poor or 
inadequate. Planimetry of the aortic valve orifice, measurement of the aortic annulus and 
detection of a bicuspid aortic valve can be performed by transoesophageal echocardiograpy. 
Cardiac catheterization is still indicated for the assessment of the severity of AS in a subset 
of patients, in whom the findings of nonivasive tests are inconclusive or if there is a 
discrepancy between the results of noninvasive investigations and clinical findings. 
Assessment of coronary anatomy is indicated before aortic valve replacement (Baumgartner 
et al. 2017, Hildebrandt et al. 2017). 
1.2.3. Low gradient aortic stenosis 
In a subset of patients with severe AS, however, the above mentioned hemodynamic 
parameters are discordant, and this poses a diagnostic dilemma. These patients may have an 
aortic valve area < 1.0 cm2 (consistent with severe AS) with a peak flow velocity < 4 m/s 
and a mean transvalvular aortic gradient < 40 mmHg (consistent with nonsevere AS). After 
careful revision of all TTE data to exclude measurement errors, the diagnosis of a LGAS is 
made (Baumgartner et al. 2009, Clavel et al. 2016, Margulescu 2017). A LGAS can be 
detected in patients with an impaired LVEF (classical low-flow LGAS) as well as in those 
with a normal LVEF (paradoxical low-flow LGAS). The classical LGAS is due to 
impairment of LVEF with the decrease of blood flow across the aortic valve secondary to a 
decrease in stroke volume. Patients with paradoxical LGAS usually have small ventricles 
with concentric hypertrophy and increased vascular impedance (Barboza et al. 2011, 
Lindman et al. 2016). 
Further diagnostic evaluation may be performed in patients with LGAS. Assessment of 
aortic valve calcification with multidetector computer tomography is recommended in 
patients with LGAS and a normal LVEF, and dobutamine stress echocardiography is 
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recommended in patients with LGAS and an abnormal LVEF for both diagnostic and 
prognostic purposes (Baumgartner et al. 2017). 
1.2.4. Treatment 
Management of AS depends on its severity, the presence of symptoms and the left ventricular 
systolic function. Once symptomatic, aortic valve replacement should be performed without 
delay. If symptom status is unclear, further tests such as exercise testing and assessment of 
B-natriuretic peptide levels may be performed for better selection of patients who are 
candidates for valve replacement (Capoulade et al. 2014, Lindman 2014). Hypertension, 
heart failure and associated coronary artery disease should be treated appropriately as in 
patients without AS. 
Medical treatment does not improve the prognosis of patients with severe symptomatic AS, 
and aortic valve replacement is the only treatment that relieves symptoms and prolongs 
survival (Otto 2006, Nishimura et al. 2014). Despite this fact, many of these patients do not 
undergo surgical valve replacement due to comorbidities that render them at high risk for 
adverse events after surgery. A substantial proportion of these patients have an impaired 
LVEF (Powell et al. 2000, Sharony et al. 2003).  
In the eighties of the last century, percutaneous balloon aortic valvuloplasty was introduced 
as a minimally invasive alternative to surgical aortic valve replacement in patients at 
prohibitive surgical risk. The enthusiasm for that novel procedure faded quickly after 
realizing that the symptomatic benefit was not durable and that balloon aortic valvuloplasty 
added no prognostic benefit compared to medical therapy alone (Sherman et al. 1989, Otto 
et al. 1994). It was not until the first-in-human percutaneous implantation of a balloon 
expandable aortic bioprosthesis in 2002 (Cribier et al. 2002) that a new era in management 
of severe AS started with an effective alternative to surgical aortic valve replacement. 
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1.3. Transcatheter aortic valve implantation 
1.3.1. Historical overview 
The percutaneous insertion of a bioprosthesis and its implantation within a severely stenotic 
aortic valve was a great achievement of modern medicine (Cribier 2012). The 57-year-old 
patient who underwent the first-in-human TAVI in the year 2002 had severe inoperable AS 
on top of a calcified bicuspid aortic valve (Cribier et al. 2002). Surgical aortic valve 
replacement was declined because of hemodynamic instability and significant comorbidities. 
Interestingly, the LVEF was 14%, the mean transvalvular aortic gradient was 30 mmHg and 
the patient showed no myocardial contractile reserve on dobutamine stress 
echocardiography. The procedure was performed using a complex antegrade transvenous, 
transseptal approach. Despite the initial rapid improvement of his cardiac symptoms and 
valve hemodynamics, the patient died 17 weeks post intervention due to non-cardiac causes 
(Cribier et al. 2002).  
The use of femoral venous access, transseptal puncture and antegrade passage of the stenotic 
aortic valve made the procedure very complicated, especially in the absence of adequate 
operators’ experience limiting its widespread application (Sakata et al. 2005). Subsequently, 
a retrograde transarterial (i.e. transfemoral) approach was introduced and simplified the 
procedure (Hanzel et al. 2005, Webb et al. 2006). This approach was used for both the 
balloon and the self-expandable prostheses that were initially available (Grube et al. 2005, 
Grube et al. 2006, Webb et al. 2006). TF-TAVI replaced rapidly the more complex antegrade 
transvenous approach. TF-TAVI, however, was not suitable for patients with small femoral 
arteries and those with advanced peripheral vascular disease. This led to the development of 
alternative access routes such as the transapical, the transsubclavian and the transaortic 
approaches. Both the balloon expandable Edwards Sapien prosthesis and the self-expandable 
CoreValve prosthesis received the Conformité Européenne (CE) mark in 2007 and became 
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commercially available in Europe. By that time, TF-TAVI and transapical TAVI were the 
most commonly used vascular access approaches. Continuous development and refinement 
of valve technology led to downsizing of the access sheaths and delivery system profiles. 
Hence, the rate of vascular access complications related to the procedure could be 
significantly reduced (Wendler et al. 2017). Thus, more patients became suitable for TF-
TAVI. Meanwhile, observational studies and randomized trials showed consistently that the 
outcomes of TF-TAVI are superior to transapical TAVI (Thomas et al. 2011, Di Mario et al. 
2013, Blackman et al. 2014, van der Boon et al. 2014, Leon et al. 2016). Consequently, TF-
TAVI became the standard procedure today with alternative vascular access routes used only 
in exceptional cases (Baumgartner et al. 2017). 
1.3.2. Indications for transcatheter aortic valve implantation 
After the first-in-human TAVI, two feasibility trials were conducted in France to study the 
safety and feasibility of percutaneous valve implantation in patients with inoperable severe 
symptomatic AS. The French Administration approved them in 2003. These trials were 
restricted to compassionate use only and recruited 36 patients. The results were promising 
with a 75% procedural success rate (Cribier et al. 2004, Cribier et al. 2006). Thereafter, many 
tertiary care centers in Europe and USA started the procedure for treatment of prohibitive 
surgical risk patients with severe symptomatic AS. A randomized Food and Drug 
Administration driven pivotal study, the Placement of Aortic Transcatheter Valves 
(PARTNER) trial, was initiated. The trial showed that TAVI was superior to standard 
medical therapy in inoperable patients (Leon et al. 2010) and not inferior to surgical aortic 
valve replacement in terms of all-cause mortality at 1-year follow-up in high risk patients 
(Smith et al. 2011). Based on these results, TAVI was approved by the Food and Drug 
Administration in 2011 for non-surgical high risk candidates. Long-term follow-up of the 
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PARTNER trial showed that the outcome of TAVI was similar to surgery at 5-year with no 
detected prosthetic valve deterioration requiring aortic valve replacement (Mack et al. 2015). 
In the 2012 European and the 2014 American guidelines for the management of valvular 
heart disease, TAVI was indicated for the treatment of symptomatic severe AS in patients 
with prohibitive surgical risk and as an alternative for surgery in patients at high risk for 
surgical aortic valve replacement (Vahanian et al. 2012, Nishimura et al. 2014). 
Further prospective randomized controlled trials consolidated the evidence for TAVI. In the 
U.S. CoreValve High Risk Study, TAVI was superior to surgical aortic valve replacement 
in terms of 1-year survival in patients at high-surgical risk (Adams  et al. 2014, Mack et al. 
2015). In the 2-year follow-up of the PARTNER-2 trial which included 2032 patients, TAVI 
was non-inferior to surgical aortic valve replacement in patients at an intermediate surgical 
risk. The outcome of TF-TAVI was even superior to surgery (Leon et al. 2016). Similar 
findings have also been shown in the Surgical Replacement and Transcatheter Aortic Valve 
Implantation (SURTAVI) trial, where 1660 patients at intermediate risk for surgery were 
randomly assigned to undergo either TAVI or surgical aortic valve replacement. At 2-year 
follow-up, all-cause mortality was similar in both groups (Reardon et al. 2017).  
Currently and according to the 2017 European guidelines for the management of valvular 
heart disease, TAVI is favored over surgery in elderly patients with severe symptomatic AS 
who are at increased surgical risk. Both TAVI and surgical aortic valve replacement can be 
used for patients with severe symptomatic AS who have an intermediate surgical risk. The 
decision to perform either procedure should be taken by a multidisciplinary heart team. 
Table 2 summarizes the conditions favoring TAVI [modified from (Baumgartner et al. 
2017)]. 
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Table 2: Factors that favor transcatheter aortic valve implantation over surgery in 
patients with symptomatic severe aortic stenosis 
Clinical characteristics 
Society of Thoracic Surgeons Score or EuroSCORE II ≥ 4% (logistic EuroSCORE ≥10%) 
Presence of severe comorbidities (not adequately reflected by scores) 
Age ≥ 75 years  
Previous cardiac surgery  
Frailty  
Restricted mobility and conditions that may affect the rehabilitation process after the 
procedure  
Anatomical and technical aspects 
Favorable access for TF-TAVI  
Sequalae of chest radiation  
Porcelain aorta  
Presence of intact coronary bypass graft at risk when sternotomy is performed  
Expected patient-prosthesis mismatch  
Severe chest deformation or scoliosis  
1.4. Impact of left ventricular ejection fraction on outcome in severe aortic stenosis  
Patients with severe AS and an impaired LVEF have a dismal prognosis if left to medical 
treatment only, and life expectancy is less than two years if symptoms of congestive heart 
failure develop (Ross and Braunwald 1968). The only effective treatment for such patients 
is to relieve the mechanical obstruction, either surgically or percutaneously (Baumgartner et 
al. 2017). Although surgical aortic valve replacement improves both the symptoms and the 
survival in this group of patients, an impaired LVEF increases both the surgical risk as well 
as the perioperative mortality, especially among those patients with a low mean transvalvular 
aortic gradient (Connolly et al. 2000, Levy et al. 2008).  
Moreover, patients with severe AS and an impaired LVEF are usually elderly, comorbid 
patients with higher surgical risk scores compared to patients with a normal LVEF and are 
usually denied aortic valve replacement surgery. Accordingly, a substantial proportion of 
patients with severe symptomatic AS and an impaired LVEF are referred for TAVI. The 
prevalence of an impaired LVEF in patients undergoing TAVI is highly variable in the 
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literature and depends on the cutoff values used, varying from 6% to 11% if a cutoff value 
< 30% was used, and from 27% to 46% if LVEF is considered impaired when between 30% 
and 50% (Bax et al. 2014).  
The association of an impaired LVEF with an increased mortality after TAVI is still 
debatable, and the cutoff value below which LVEF has a significant impact on mortality is 
not consistent throughout the available studies. Moreover, a proportion of patients with an 
impaired LVEF has LGAS, a combination that may further increase the risk of an adverse 
outcome in these patients. 
1.5. Cutoff values for left ventricular ejection fraction 
LVEF is considered a powerful predictor of clinical outcome in patients with cardiovascular 
diseases including AS (Quere et al. 2006). LVEF is usually measured by means of two-
dimensional TTE using the modified Simpson’s method to estimate the left ventricular end 
diastolic and end systolic volumes.  
Recently, new cutoff values were recommended for the assessment of LVEF by the ASE 
and the EACVI. This classification provides gender-specific cutoff values for a normal 
LVEF (table 3). These normal reference values for LVEF derived from 2-dimensional TTE 
have been updated using population based studies, and the cutoff value for normal represents 
two standard deviations around the mean in healthy adults (Lang et al. 2015). Furthermore, 
impairment of LVEF in these recommendations is subdivided into 3 categories of severity. 
Such a detailed sub-classification of an impaired LVEF was not used in previous studies 
assessing the impact of LVEF on outcome after TAVI. Likewise, the different cutoff values 
for a normal LVEF in males and females are not yet adopted in practice clinical guidelines, 
which consider LVEF to be normal when ≥ 50% in both genders (Nishimura et al. 2014, 
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Baumgartner et al. 2017). The significance of this difference in patients with severe AS is 
unknown.  
Nevertheless, the importance of a detailed categorization of the impairment of LVEF was 
recently addressed by the latest European guidelines for the management of patients with 
acute and chronic heart failure, which has introduced the new category of heart failure with 
mid-range LVEF, underlining the need of more clinical data on outcomes of patients with a 
mildly abnormal LVEF (Ponikowski et al. 2016). 
Table 3: Classification of the impairment of left ventricular ejection fraction 
Left ventricular ejection fraction (%) 
 
Normal 
range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
Female 54-74 41-53 30-40 <30 
Male 52-72 41-51 30-40 <30 
Adopted from (Lang et al. 2015) 
1.6. Aim of the study 
The aim of this retrospective analysis was to evaluate the impact of baseline LVEF, classified 
according to the 2015 ASE/EACVI recommendations, on 30-day and 1-year all-cause 
mortality after TF-TAVI and to assess the impact of the possible interaction between 
baseline LVEF and mean transvalvular aortic gradient on outcome in these patients. 
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2. Materials and Methods 
2.1. Patient population 
We retrospectively analyzed the clinical data of all patients with severe AS who underwent 
TF-TAVI at the West German Heart and Vascular Center Essen between January 2006 and 
July 2015. All patients had severe symptomatic AS and were considered to be at a prohibitive 
or high risk for surgical aortic valve replacement based on a logistic EuroSCORE > 15% 
(Smith et al. 2011) or the presence of comorbidities that increase the operative surgical risk 
such as porcelain aorta, liver cirrhosis, previous chest radiation, previous coronary artery 
bypass surgery with a patent left internal mammary artery graft. All patients had an 
angiogram of their aorta and pelvic arteries, and the femoral access site was considered 
suitable for the delivery of the TAVI-system. Patient selection for TF-TAVI was done by 
the institutional heart team consisting of an interventional cardiologist, cardiothoracic 
surgeon and cardiac anesthesiologist. 
Patients were excluded from the study if the baseline TTE was not performed in our center, 
if the indication for TAVI was other than severe native AS or if TF-TAVI could not be 
performed. This analysis was approved by the local ethics committee (17-7610-BO), and 
patient consent was waived due to the retrospective nature of the analysis.  
Demographic and procedural data were obtained from the hospital’s medical records. The 
following patient characteristics were collected: 
▪ Demographics: age, gender, body mass index defined as body weight/(body height)2 
(kg/m2) 
▪ Comorbidities: chronic obstructive pulmonary disease; pulmonary hypertension 
defined as pulmonary artery systolic pressure > 60 mmHg; recent myocardial 
infarction defined as myocardial infarction within 90 days before TAVI; extracardiac 
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arteriopathy defined as the presence of claudication, carotid occlusion or > 50% 
stenosis and/or previous or planned intervention on the abdominal aorta, limb arteries 
or carotids (Roques et al. 2003); diabetes mellitus; chronic kidney disease (CKD) 
categorized into mild/absent if the glomerular filtration rate was > 60 ml/min/1.73m2, 
moderate if between 30 and 60 ml/min/1.73m2 and severe if  < 30 ml/min/1.73m2 
(Piepoli et al. 2016); permanent atrial fibrillation; the presence of permanent 
pacemaker/implantable cardioverter defibrillator before TF-TAVI; and presence of 
coronary artery disease defined as a stenosis > 50% in diameter of a major epicardial 
coronary artery, a history of coronary artery bypass graft surgery, a history of 
percutaneous coronary intervention or performance of a percutaneous coronary 
intervention during patient preparation for TF-TAVI. 
▪ Laboratory values:  serum creatinine (the latest in-hospital serum value on the day 
before TF-TAVI), glomerular filtration rate in ml/min/1.73m2 as calculated from 
serum creatinine level according to the Modification of Diet in Renal Disease 
equation (Levey et al. 2006). 
▪ Assessment of the operative risk using the logistic EuroSCORE  (Roques et al. 2003). 
2.2. Determination of left ventricular ejection fraction  
The following data were extracted from TTE reports or offline analysis of the saved 
corresponding TTE studies, as needed: baseline LVEF, mean transvalvular aortic gradient, 
aortic valve area, grade of concomitant aortic regurgitation and grade of concomitant mitral 
regurgitation. If baseline LVEF was not precisely documented in the TTE report, the exact 
LVEF value was obtained by offline analysis of the original TTE study loops stored in our 
DICOM archive (McKesson Workstation, McKesson, Tel Aviv) from standard 2-
dimensional apical views according to the 2015 ASE/EACVI recommendations for cardiac 
chamber quantification by echocardiography (Lang et al. 2015). In this case, the left 
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ventricular endocardial border was traced manually from end-diastolic and end-systolic 
apical frames. The workstations’ software provided automatically the corresponding left 
ventricular end-diastolic and left ventricular end-systolic volumes (LVEDV and LVESV, 
respectively) calculated by modified Simpson’s method. LVEF was then calculated as: 
LVEF (%) = (LVEDV – LVESV) / LVEDV 
All LVEF data were collected by two independent reviewers. In case of disagreement, the 
LVEF was determined by consensus. LVEF data were then entered and locked in the local 
TF-TAVI database before the start of data analysis.  
Patients were divided into four groups according to their baseline LVEF following the 2015 
recommendations of the ASE/EACVI for cardiac chamber quantification by 
echocardiography: a normal LVEF, defined as a baseline LVEF > 51% in males or > 53% 
in females, a mildly abnormal LVEF, defined as a baseline LVEF > 40% and  51% in males 
or > 40% and  53% in females, a moderately abnormal LVEF, defined as a baseline LVEF 
≥ 30% and  40% and a severely abnormal LVEF, defined as a baseline LVEF <30% (Lang 
et al. 2015). 
The value of the mean transvalvular aortic gradient was obtained from TTE reports. Patients 
were considered to have LGAS if the mean transvalvular aortic gradient at baseline was < 
40 mmHg (Clavel et al. 2016) as determined from the continuous wave Doppler spectrum 
analysis across the aortic valve from multiple echocardiographic windows during TTE 
examination, taking the continuous wave Doppler spectrum with the highest recorded 
Doppler velocity. The commercially available echocardiography machine software (iE33; 
Philips Medical Systems, Andover, MA and Vivid E9 Ultrasound system; GE Healthcare, 
Waukesha, WI) provided automatically the velocity time integral and the mean transvalvular 
aortic gradient upon manual tracing of the continuous wave Doppler spectrum.  
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Aortic valve area was obtained from TTE reports, where it was calculated from the left 
ventricular outflow tract diameter measured in the parasternal long axis view (LVOTd), the 
velocity time integral of the pulsed wave Doppler signal recorded from apical views with 
the sample volume placed in the left ventricular outflow tract (LVOTVTI) and the velocity 
time integral of the highest continuous wave velocity signal across the aortic valve (AVVTI) 
according to the continuity equation: 
Aortic valve area = π * (LVOTd/2)2 * LVOTVTI / AVVTI 
Mitral regurgitation severity and aortic regurgitation severity were obtained from TTE 
reports and graded according to the guidelines for management of valvular heart diseases 
(Vahanian et al. 2012).  For this analysis, mitral or aortic regurgitation was considered 
significant if it was moderate or severe. 
2.3. Transfemoral aortic valve implantation procedure 
TF-TAVI procedures were performed in a hybrid operating room (Bonatti et al. 2007) using 
either the successive generations of the balloon expandable Edwards bioprosthesis (Cribier 
Edwards, Edwards Sapien, Edwards Sapien XT and Sapien 3, Edwards Lifesciences, Irvine, 
CA, USA) or the self-expandable Medtronic CoreValve device (CoreValve, CoreValve 
Evolut, Medtronic, Minneapolis, MN, USA) in a standardized fashion. The procedure was 
predominantly performed under conscious sedation monitored by a cardiac anesthesiologist. 
Invasive hemodynamics and electrocardiographic data of the patient were monitored 
continuously during the procedure from an arterial catheter and a central venous catheter as 
well as a 12-lead electrocardiogram. Premedications included acetyl salicylic acid (100mg 
daily) and clopidogrel (300mg loading dose, then 75mg daily) and a single intravenous dose 
of ceftriaxone 2g before the procedure. The procedure was performed under anticoagulation 
with intravenous heparin aiming at an activated clotting time between 250 and 300 seconds 
during the procedure. The arterial access of the common femoral artery on one side was 
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gained using Seldinger’s technique to introduce a 6 French arterial sheath and a pigtail 
catheter in the descending thoracic aorta above the level of the aortic bifurcation. Then 
fluoroscopically guided arterial access of the other common femoral artery was gained in a 
similar fashion, and a suture-mediated closure device was pre-deployed with the sutures 
secured with a mosquito forceps till the end of the procedure. The sheath was then exchanged 
over a stiff wire for the required device sheath (14 French to 24 French according to device 
type, size and generation). The contralateral pigtail was then pushed to the aortic root to 
perform contrast injections as needed during the procedure. The aortic valve was crossed 
with a straight-tip wire guided by an Amplatz left catheter and simultaneous left ventricular 
and aortic pressure curves were recorded. Afterwards, the wire was exchanged for a stiff pre-
shaped wire. Valvuloplasty of the aortic valve was then performed under rapid right 
ventricular pacing (180 to 200 beats per minute), followed by implantation of either the 
balloon expandable prosthesis under a similar pacing rate or the self-expandable prosthesis 
under a slower pacing rate between 110 and 130 beats per minute. After prosthesis 
implantation, position and grade of aortic regurgitation were assessed angiographically. 
Invasive simultaneous left ventricular and aortic pressure curves were registered again 
followed by withdrawal of the device sheath and tying the sutures of the preloaded closure 
device. Angiography of the aorto-iliac bifurcation was performed to ascertain the successful 
closure of the arterial access and the other puncture side was then closed in a standard 
manner. A pressure bandage was then fixed for 24 hours with regular check-up of limb 
perfusion and signs of bleeding (Kahlert et al. 2008, Patsalis et al. 2013, Kahlert et al. 2017). 
Procedural outcomes were defined according to the Valve Academic Research Consortium-
2 (VARC-2) criteria (Kappetein et al. 2012).  
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2.4. Follow-up 
Mortality data were obtained from hospital records and from telephone contact with the 
patients, their relatives or their primary care physicians. Patients were censored at the day of 
death or at completion of 1-year follow-up, whichever came first. Patient inclusion ended in 
July 2015, hence, 1-year mortality status was available for all patients.  
Baseline clinical, procedural and mortality data were compared between the categories of 
LVEF. We also compared the outcome of patients with LGAS and those without LGAS in 
the whole study population, as well as within each category of LVEF. 
2.5. Statistical analysis 
Categorical variables were presented as count (percentage). The normality of distribution of 
continuous variables was tested with the Kolmogorov-Smirnov test. Normally distributed 
variables were presented as mean  standard deviation, whereas skewed data were presented 
as median (lower quartile, upper quartile). The patients were divided into four groups 
according to their baseline LVEF and into two groups according to the presence of LGAS. 
The comparisons between the study groups were performed with the Chi-square or Fischer’s 
exact test for categorical variables or Kruskal-Wallis test for continuous variables. The 
correlation between baseline LVEF and mean aortic transvalvular gradient was tested with 
Spearman’s rho method.  
The impact of baseline LVEF and LGAS on all-cause mortality was tested using the Kaplan-
Meier method. Patients were censored at the time of death or at completion of 1-year follow-
up, whichever came first and the Kaplan-Meier curves were compared visually and with log-
rank test (Bewick et al. 2004, Zwiener et al. 2011). 
To identify the predictors of 30-day and 1-year mortality, survival analysis was performed 
using the Cox regression method. Variables entered in the univariate analysis included age, 
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gender, CKD, diabetes mellitus, extracardiac arteriopathy, coronary artery disease, previous 
coronary artery bypass graft surgery, previous percutaneous coronary intervention, recent 
myocardial infarction, atrial fibrillation, previous permanent pacemaker or implantable 
cardioverter defibrillator implantation, pulmonary hypertension, significant mitral 
regurgitation, LVEF, LGAS, aortic valve area, logistic EuroSCORE and type of implanted 
prosthesis. Based on the results of Kaplan-Meier analysis, baseline LVEF was entered in the 
univariate Cox regression model as well as in the subsequent multivariate regression models 
as a dichotomous variable with a cutoff point of 40% (> 40% versus  40%) (Zwiener et al. 
2011). This cutoff point represents the cutoff point between mildly abnormal and moderately 
abnormal LVEF (Lang et al. 2015). 
Variables with a p-value < 0.2 in the univariate analysis were introduced into a Cox 
multivariate regression analysis using a stepwise forward selection method. A predefined 
multivariate Cox regression model with the same variables and, in addition, the interaction 
term abnormal LVEF*LGAS, was also constructed.  
All p-values were two-sided and considered statistically significant when < 0.05.  
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3. Results 
3.1. Patient characteristics 
Five-hundred-eighty-five TF-TAVI procedures were performed in 581 patients between 
January 2006 and July 2015. Four patients had two TF-TAVI procedures during the study 
period. In two patients, the index TF-TAVI was aborted (and excluded from this analysis) 
due to a large native aortic annulus not permitting the implantation of the largest aortic valve 
prosthesis available at time. In each case, another TF-TAVI procedure was performed few 
months later after commercial availability of the larger aortic valve prosthesis. The latter 
procedure was included in this analysis. In the other two patients, the grade of paravalvular 
leak was considered clinically significant during follow-up and a second TF-TAVI 
procedure was later performed to seal the leak as a so-called valve-in-valve procedure. In 
both cases, only the index TF-TAVI was included in this analysis. According to the 
predefined exclusion criteria for this study, 76 patients were also excluded for the following 
reasons:  
1. Baseline TTE was performed only in the referring hospital (55 patients). 
2. TF-TAVI was performed for a degenerated surgical bioprosthesis as a valve-in-valve 
procedure (18 patients). 
3. TF-TAVI was performed for native aortic regurgitation (1 patient). 
4. TF-TAVI was performed for the treatment of a stenotic bicuspid aortic valve (1 
patient). 
5. TF-TAVI was aborted due to a too large native aortic annulus without a subsequent 
procedure (1 patient).  
After exclusion of these patients, 505 patients were included in this analysis (figure 1)
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Figure 1: Flow chart of the patient selection 
 
 
585 TF-TAVI in 581 patients 
505 TF-TAVI in 505 patients were included 
80 TF-TAVI procedures were excluded: 
- TF-TAVI was performed for severe aortic regurgitation (1 patient)
- TF-TAVI was performed for bicuspid aortic valve (1 patient)
- TF-TAVI was aborted (1 patient)
- Valve-in-Valve TF-TAVI for degenerative bioprosthesis (18 patients)
- Baseline TTE was not performed in our center (55 patients)
- Two TF-TAVI procedures were performed in the same patient (4 patients)
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The median age of these patients was 82 (78, 85) years, 277 (55%) were female and the 
logistic EuroSCORE was 14.4% (9%, 22.7%). Coronary artery disease was present in 278 
(55%) patients. Sixty-two (12%) patients had prior coronary artery bypass graft surgery and 
203 (40%) patients had prior percutaneous coronary intervention. Diabetes mellitus was 
present in 198 (39%) patients. Three-hundred-seventy-six (74%) patients had at least 
moderate CKD. 
3.2. Procedural data 
The balloon expandable (Cribier Edwards, Edwards Sapien, Edwards Sapien XT and Sapien 
3, Edwards Lifesciences, Irvine, CA, USA) bioprosthesis was implanted in 408 (81%) 
patients, while the self-expandable (CoreValve and Evolut, Medtronic, Minnepolis, MN, 
USA) bioprosthesis was implanted in 97 (19%) patients. TF-TAVI was performed without 
preparatory balloon aortic valvuloplasty in 16 (3%) patients, mostly during the implantation 
of the self-expandable prosthesis (13 patients, p < 0.001). Post dilatation was performed in 
41 (8%) patients and was more common with the self-expandable prosthesis [21 (20%) 
patients versus 20 (5%) patients, p < 0.001] than with the balloon expandable prosthesis. The 
median volume of contrast medium used during the procedure was 210 (169, 270) ml and 
was not significantly different between the self-expandable [200 (150, 251) ml] and the 
balloon expandable prosthesis [210 (173, 273) ml], p = 0.073. VARC-2 procedural outcomes 
were comparable between both prostheses types and are summarized in table 4.
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Table 4: Procedural outcomes of transfemoral aortic valve implantation 
 
All patients 
(n = 505) 
Balloon expandable prosthesis 
(n = 408) 
Self-expandable prosthesis 
(n = 97) 
p 
Coronary artery obstruction 4 (< 1) 4 (< 1) 0 1 
Conversion to open heart surgery 3 (< 1) 3 (< 1) 0 1 
Ventricular perforation  6 (1) 6 (1.5) 0 0.601 
Myocardial infarction after TF-TAVI 10 (2) 10 (2.5) 0 0.221 
- Periprocedural 6 (1) 6 (1.5) 0 0.601 
- Spontaneous 4 (< 1) 4 (< 1) 0 1 
Pericardial tamponade 6 (1) 6 (1.5) 0 0.601 
Post procedural stroke  20 (4) 18 (4) 2 (2) 0.392 
- Major 10 (2) 8 (2) 2 (2) 1 
- Minor 10 (2) 10 (2.5) 0 0.221 
Post procedural bleeding 69 (14) 57 (14) 12 (12) 0.68 
- Life threatening 17 (3) 16 (4) 1 (1) 0.216 
- Major 31 (6) 26 (6) 5 (5) 0.653 
- Minor 21 (4) 15 (4) 6 (6) 0.262 
Vascular complications 89 (18) 71 (17) 18 (19) 0.788 
- Major  59 (12) 47 (12) 12 (12) 0.814 
- Minor  30 (6) 24 (6) 6 (6) 0.91 
Acute kidney injury 111 (22) 90 (22) 21 (22) 0.93 
- Grade 1 64 (13) 49 (12) 15 (16) 0.358 
- Grade 2 26 (5) 21 (5) 5 (5) 1 
- Grade 3 21 (4) 20 (5) 1 (1) 0.096 
Data are presented as count (percentage). TF-TAVI = transfemoral aortic valve implantation. 
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3.3. Echocardiographic data 
Baseline LVEF was 54% (44%, 59%), mean transvalvular aortic gradient was 45 (43, 57) 
mmHg and aortic valve area was 0.7 (0.52, 0.84) cm2 in the entire patient population. 
Significant mitral and aortic regurgitation at baseline were present in 221 (44%) and 87 
(17%) patients, respectively.  
Baseline LVEF was normal in 280 (55%), mildly abnormal in 121 (24%), moderately 
abnormal in 74 (15%) and severely abnormal in 30 (6%) patients, respectively.  
Mean transvalvular aortic gradients correlated significantly with the degree of LVEF 
impairment (Spearman’s rho = 0.25, p < 0.001), and LGAS was present in 192 (38%) 
patients. The prevalence of LGAS was higher in patients with a severely (23 patients, 77%) 
and a moderately abnormal LVEF (44 patients, 60%) compared to patients with a mildly 
abnormal (36 patients, 30%) and a normal LVEF (89 patients, 32%).  
The calculated aortic valve area was smaller in patients with a moderately abnormal LVEF 
compared to patients with a normal LVEF (p < 0.05), and patients with a moderately 
abnormal LVEF had a higher incidence of concomitant significant mitral regurgitation 
compared to the other groups. The findings of the baseline TTE study are presented in table 
5.
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Table 5: Baseline echocardiographic findings 
LVEF 
All patients 
(n = 505) 
Normal  
(n=280)  
Mildly 
abnormal  
(n=121) 
Moderately 
abnormal  
(n=74) 
Severely 
abnormal  
(n=30) 
p 
Time interval from TTE to TF-TAVI (days) 12 (6, 25) 11 (5,25) 12 (6,24) 13 (7,28) 15 (5,31) 0.373 
LVEF (%) 54 (44, 59) 58 (55, 63) 49 (45,51) 36 (32,38) 25 (20,27) _ 
Mean transvalvular aortic gradient (mmHg) 45 (33, 57) 48 (36, 61) 47 (36,61) 36 (27,50)# 26 (20,39)# < 0.001 
Aortic valve area (cm2) 0.7 (0.5, 0.8) 0.7 (0.59,0.9) 0.67(0.5,0.8) 0.68 (0.5,0.8)* 0.6 (0.42,0.92) 0.013 
LGAS 192 (38) 89 (32) 36 (30) 44 (60)# 23 (77)# < 0.001 
Significant mitral regurgitation 221 (44) 109 (39) 51 (42) 48 (65)# 13 (43) 0.001 
Significant aortic regurgitation 87 (17) 53 (19) 20 (17) 10 (14) 4 (13) 0.649 
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
* p < 0.05 compared to patients with a normal LVEF 
# p < 0.01 compared to patients with a normal LVEF 
LGAS = low gradient aortic stenosis, LVEF = left ventricular ejection fraction, TTE = transthoracic echocardiography, TF-
TAVI = transfemoral aortic valve implantation.  
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3.4. Patient characteristics and procedural data stratified by baseline ejection fraction 
3.4.1. Differences in patient characteristics 
Age of the patients was similar across the study groups. Males represented the majority of 
patients in the groups with a moderately and a severely abnormal LVEF (65% and 60%, 
respectively), whereas the groups with a normal and a mildly abnormal LVEF showed 
female predominance (59% and 61%, respectively, p < 0.001). The prevalence of coronary 
artery disease was more common in patients with a moderately abnormal LVEF (69%, p < 
0.01) and in patients with a severely abnormal LVEF (73%, p < 0.05) than in patients with 
a normal LVEF (49%). Extracardiac arterial disease was more common in patients with a 
moderately abnormal LVEF (34%, p < 0.001) compared to patients with a normal LVEF 
(20%). Patients with a normal LVEF had significantly less frequent permanent pacemakers 
and implantable cardiac defibrillators than those with a mildly, a moderately and a severely 
abnormal LVEF (10%, 17%, 27%, 37% respectively, p < 0.001). Severe CKD was more 
common in patients with a severely abnormal LVEF (27%, p < 0.01) compared to patients 
with a normal LVEF (9%). The logistic EuroSCORE in patients with a moderately abnormal 
LVEF (22.5%) and in patients with a severely abnormal LVEF (30.8%) was significantly 
higher compared to patients with a normal LVEF (11.1%, p < 0.01). Apart from more 
frequent implantable pacemaker or cardioverter defibrillator devices in patients with a mildly 
abnormal LVEF compared to patients with a normal LVEF, there were no significant 
differences in baseline characteristics between both patient groups. These results are 
summarized in table 6.
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Table 6: Patient characteristics stratified by baseline ejection fraction 
LVEF 
All patients 
(n = 505) 
Normal  
(n = 280) 
Mildly 
abnormal  
(n = 121) 
Moderately 
abnormal  
(n = 74) 
Severely 
abnormal  
(n = 30) 
p 
Age (years) 82 (78, 85) 82 (78, 85) 83 (78, 86) 82 (77, 87) 80 (74, 83) 0.57 
Female 277 (55) 165 (59) 74 (61) 26 (35)# 12 (40)* < 0.001 
BMI (kg/m2) 26.4 (23.9,29.8) 26.6 (24.1,29.7) 25.9 (23.5, 8.9) 26.8 (23, 30.4) 26 (22.2, 31.6) 0.678 
Logistic EuroSCORE (%) 14.4 (9, 22.7) 11.1 (7.8, 18) 15.5 (10.5,21.5) 22.5 (12.8,30.5)# 30.8 (22.4,35.1)# < 0.001 
COPD 111 (22) 71 (25) 20 (24) 14 (19) 6 (20) 0.218 
Extracardiac arteriopathy 124 (25) 57 (20) 31 (26) 25 (34)# 11 (37) 0.036 
Recent MI 17 (3) 5 (2) 5 (4) 3 (4) 4 (13)# 0.015 
Pulmonary hypertension 99 (20) 46 (16) 27 (22) 17 (23) 9 (30) 0.176 
Coronary artery disease 278 (55) 138 (49) 67 (55) 51 (69)# 22 (73)* 0.004 
Previous PCI 203 (40) 103 (37) 50 (41) 37 (50) 13 (43) 0.212 
Previous CABG 62 (12) 27 (10) 15 (12) 15 (20) 5 (17) 0.076 
Diabetes mellitus 198 (39) 105 (38) 46 (38) 35 (47) 12 (40) 0.484 
Atrial fibrillation 156 (31) 78 (28) 39 (32) 29 (39) 10 (33) 0.286 
Previous PPM/ ICD  81 (16) 29 (10) 21 (17)* 20 (27)# 11 (37)# < 0.001 
Serum creatinine (mg/dl) 1.3 (1.1, 1.6) 1.23 (1.03,1.56) 1.25 (1.07,1.58) 1.37 (1.19, 1.82)# 1.53 (1.2, 2.11)# < 0.001 
GFR(ml/min/1.73m2) 49 (39, 60) 50 (39, 60) 49 (38, 61) 46 (36, 56) 44 (26, 55) 0.052 
CKD      0.037 
- No/ Mild 129 (26) 78 (28) 33 (27) 14 (19) 4 (13)  
- Moderate 313 (62) 177 (63) 69 (57) 49 (66) 18 (60)  
- Severe 63 (12) 25 (9) 19 (16) 11 (15) 8 (27)#  
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
* p < 0.05 compared to patients with a normal LVEF, # p < 0.01 compared to patients with a normal LVEF 
BMI = body mass index, CABG = coronary artery bypass surgery, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary 
disease, ICD = implantable cardioverter defibrillator, GFR = glomerular filtration rate, LVEF = left ventricular ejection fraction, MI = 
myocardial infarction, PCI = percutaneous coronary intervention, PPM = permanent pacemaker.   
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3.4.2. Baseline parameters in patients with low and high mean transvalvular aortic 
gradient 
Patients with LGAS tended to be younger (81 years versus 82 years, p = 0.069), had a higher 
logistic EuroSCORE (17.2% versus 12.8%, p < 0.001) and a higher prevalence of coronary 
artery disease (66% versus 48%, p < 0.001), extracardiac arterial disease (30% versus 22%, 
p = 0.021), diabetes mellitus (45% versus 36%, p = 0.044) as well as atrial fibrillation (39% 
versus 26%, p = 0.004) than those without LGAS. Females constituted 48% of patients with 
LGAS compared to 59% of patients without LGAS (p =0.023). Serum creatinine was higher 
in patients with LGAS than those without LGAS but the prevalence of CKD was similar in 
both groups (p = 0.231). LVEF (51% versus 55%, p < 0.001) and aortic valve area (0.62 cm2 
versus 0.8 cm2, p < 0.001) were lower in patients with LGAS than in patients without LGAS. 
These data are presented in table 7. 
3.4.3. Procedural data stratified by baseline ejection fraction and mean transvalvular 
aortic gradient 
The self-expandable prosthesis was implanted in 37% of the patients with a severely 
abnormal LVEF, in 28% of patients with a moderately abnormal LVEF, in 21% of patients 
with a mildly abnormal LVEF and in 14% of patients with a normal LVEF (p = 0.002). TF-
TAVI was performed without preparatory balloon valvuloplasty in 16 (3%) patients, more 
commonly in patients with a severely (7%) and a moderately abnormal LVEF (12%) than in 
patients with a mildly abnormal (2.5%) and a normal LVEF (3%, p < 0.001). Post dilatation 
of the implanted prosthesis was least frequent in patients with a normal LVEF (4%) and most 
frequent in patients with a severely abnormal LVEF (23%, p < 0.001). Procedural outcomes 
were comparable between the groups of LVEF and in patients with and without LGAS. The 
procedural data for the different groups of baseline LVEF are presented in table 8 and for 
patients with LGAS compared to patients without LGAS in table 9.  
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Table 7: Baseline characteristics and echocardiographic findings in patients with and 
without low gradient aortic stenosis 
 
not LGAS 
(n = 313) 
LGAS 
(n = 192) 
p 
Age (years) 82 (78, 86) 81 (77, 84.5) 0.069 
Female 184 (59) 93 (48) 0.023 
BMI (kg/m2) 26.4 (24, 29.8) 26.4 (23.4, 29.9) 0.944 
Logistic EuroSCORE (%) 12.8 (8.4, 19.5) 17.2 (10.8, 27.1) < 0.001 
COPD 67 (21) 44 (23) 0.691 
Extracardiac arteriopathy 66 (21) 58 (30) 0.021 
Recent MI 6 (2) 11(6) 0.021 
Pulmonary hypertension 62 (20) 37 (19) 0.883 
Coronary artery disease 151 (48) 127 (66) < 0.001 
Previous PCI 111 (36) 92 (48) 0.006 
Previous CABG 24 (8) 38 (20) < 0.001 
Diabetes mellitus 112 (36) 86 (45) 0.044 
Atrial fibrillation 82 (26) 118 (39) 0.004 
Previous PPM/ ICD  39 (13) 42 (22) 0.005 
Serum creatinine (mg/dl) 1.24 (1.07, 1.52) 1.33 (1.1, 1.67) 0.025 
GFR (ml/min/1.73m2) 50 (39, 61) 47 (37, 57) 0.066 
CKD   0.235 
- No/ Mild 88 (28) 41 (21)  
- Moderate 188 (60) 125 (65)  
- Severe 37 (12) 26 (14)  
Time interval from TTE to TF-
TAVI (days) 
11 (6, 21) 13 (6, 29) 0.108 
LVEF (%) 55 (49, 60) 51 (36, 58) < 0.001 
Mean transvalvular aortic gradient 
(mmHg) 
53 (46, 64) 30 (22, 25) _ 
Aortic valve area (cm2) 0.8 (0.61, 0.93) 0.62 (0.5, 0.78) < 0.001 
Significant mitral regurgitation 136 (44) 85 (44) 0.857 
Significant aortic regurgitation 61 (20) 26 (14) 0.086 
Data are presented as count (percentage) or median (25th percentile, 75th percentile).  
BMI = body mass index, CABG = coronary artery bypass surgery, CKD = chronic kidney 
disease, COPD = chronic obstructive pulmonary disease, ICD = implantable cardioverter 
defibrillator, GFR = glomerular filtration rate, LGAS = low gradient aortic stenosis, 
LVEF = left ventricular ejection fraction, MI = myocardial infarction, PCI = 
percutaneous coronary intervention, PPM = permanent pacemaker, TF-TAVI = 
transfemoral aortic valve implantation, TTE = transthoracic echocardiography.   
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              Table 8: Procedural data stratified by baseline left ventricular ejection fraction 
LVEF  
All patients 
(n = 505) 
Normal  
(n = 280) 
Mildly 
abnormal  
(n =121) 
Moderately 
abnormal 
 (n = 74) 
Severely 
abnormal  
(n = 30) 
p 
Self-expandable prosthesis 97 (19) 40 (14) 25 (21) 21 (28)# 11 (37)# 0.002 
Post-dilatation 41 (8) 11 (4) 13 (11)* 10 (13.5)# 7 (23)# < 0.001 
TF-TAVI without BAV 16 (3) 2 (1) 3 (2.5) 9 (12)# 2 (7)# < 0.001 
Contrast medium (ml) 210(169,270) 210 (173,279) 200 (160,254) 220 (181,288) 197 (155,247) 0.326 
Coronary artery obstruction 4 (< 1) 4 (1) 0 0 0 0.356 
Conversion to open heart surgery 3 (< 1) 1 (< 1) 2 (2) 0 0 0.364 
Ventricular perforation  6 (1) 5 (2) 1 (< 1) 0 0 0.525 
MI after TF-TAVI 10 (2) 8 (3) 1 (< 1) 1 (1) 0 0.441 
- Periprocedural  6 (1) 6 (2) 0 0 0 0.181 
- Spontaneous  4 (< 1) 2 (< 1) 1 (< 1) 1 (1) 0 0.906 
Pericardial tamponade 6 (1) 6 (2) 0 0 0 0.181 
Post procedural stroke  20 (4) 11 (4) 3 (2.5) 5 (7) 1 (3) 0.522 
- Major  10 (2) 4 (< 1) 3 (2.5) 3 (4) 0 0.417 
- Minor  10 (2) 7 (2.5) 1 (< 1) 2 (1) 1 (3) 0.686 
Post procedural bleeding 69 (14) 31 (11) 18 (15) 12 (16) 5 (17) 0.509 
- Life threatening  17 (3) 13 (5) 3 (2.5) 1 (1) 0 0.3 
- Major  31 (6) 11 (4) 9 (7) 8 (11) 3 (10) 0.098 
- Minor  21 (4) 8 (3) 6 (5) 5 (7) 2 (7) 0.375 
Vascular complications 89 (18) 48 (17) 23 (19) 12 (16) 6 (20) 0.936 
- Major  59 (12) 33 (12) 12 (10) 9 (12) 5 (17) 0.775 
- Minor  30 (6) 15 (5) 11 (9) 3 (4) 1 (3) 0.368 
Acute kidney injury 111 (22) 65 (23) 20 (17) 17 (23) 9 (30) 0.319 
- Grade 1 64 (13) 37 (13) 14 (12) 7 (9.5) 6 (20) 0.502 
- Grade 2 26 (5) 16 (6) 2 (2) 7 (9.5) 1 (3) 0.101 
- Grade 3 21 (4) 12 (4) 4 (3) 3 (4) 2 (7) 0.871 
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
* p < 0.05 compared to patients with a normal LVEF 
# p < 0.01 compared to patients with a normal LVEF 
BAV = balloon aortic valvuloplasty, TF-TAVI = transfemoral aortic valve implantation.   
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Table 9: Procedural data in patients with and without low gradient severe aortic 
stenosis 
 
Not LGAS 
(n = 313) 
LGAS 
(n = 192) 
p 
Self-expandable prosthesis 53 (17) 44 (23) 0.098 
Post-dilatation 21 (7) 20 (10) 0.139 
TF-TAVI without BAV 6 (2) 10 (5) 0.04 
Contrast medium (ml) 206 (160, 272) 210 (180, 271) 0.309 
Coronary artery obstruction 4 (1) 0 0.303 
Conversion to open heart surgery 2 (0.6) 1 (0.5) 1 
Ventricular perforation  5 (1.6) 1 (0.5) 0.415 
Myocardial infarction after TF-TAVI 7 (2.2) 3 (1.6) 0.749 
- Periprocedural 5 (1.6) 1 (0.5) 0.415 
- Spontaneous 2 (0.6) 2 (1) 0.637 
Pericardial tamponade 4 (1.3) 2 (1) 1 
Post procedural stroke  11 (3.5) 9 (4.7) 0.512 
- Major  5 (1.6) 5 (2.6) 0.516 
- Minor 6 (1.9) 4 (2.1) 1 
Post procedural bleeding 40 (13) 29 (15) 0.46 
- Life threatening 12 (3.8) 5 (2.6) 0.457 
- Major  17 (5.4) 14 (7.3) 0.398 
- Minor  11 (3.5) 10 (5.2) 0.355 
Vascular complications 53 (17) 36 (19) 0.603 
- Major 34 (11) 25 (13) 0.464 
- Minor  19 (6) 11 (6) 0.875 
Acute kidney injury 71 (23) 40 (21) 0.626 
- Grade 1 42 (13) 22 (12) 0.52 
- Grade 2 16 (5) 10 (5) 0.962 
- Grade 3 13 (4) 8 (4) 0.994 
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
BAV = balloon aortic valvuloplasty, TF-TAVI = transfemoral aortic valve implantation.   
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3.5. All-cause mortality after transfemoral aortic valve implantation 
3.5.1. Thirty-day and one-year mortality  
At the end of 1-year follow-up, 113 patients died (22.4%). Of these, 43 patients (8.5%) died 
within 30 days after TF-TAVI. Patients who died at 30 days had a significantly higher 
logistic EuroSCORE [19.2% (10.7%, 28.9%) versus 13.9% (9%, 22.2%), p = 0.24], and 
lower mean transvalvular aortic gradients [37 (20, 52) mmHg versus 45 (34, 54) mmHg, p 
= 0.004] than 30-day survivors. The comparison of baseline and echocardiographic data 
between both groups is summarized in table 10. 
At 1-year follow-up, patients who died had both a lower LVEF [52% (37%, 58%) versus 
55% (45%, 59%), p = 0.045] and a lower mean transvalvular aortic gradient [40 (26, 51) 
mmHg versus 47 (35, 59) mmHg, p < 0.001] than survivors. Male patients had a higher 1-
year mortality compared to females (29% versus 17%, p = 0.01). Baseline serum creatinine 
was higher in patients who died than in survivors, but the glomerular filtration rate and 
grades of CKD were similar in both groups. These data are summarized in table 11. 
There was no significant difference in the 30-day mortality between patients receiving the 
self-expandable prosthesis and those receiving the balloon expandable prosthesis (10% 
versus 8%, p = 0.505). One-year mortality was numerically higher in patients who received 
the self-expandable prosthesis, yet statistically non-significant (27% versus 21%, p = 0.231).  
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Table 10: Baseline characteristics and echocardiographic data of patients who died and 
patients who survived at thirty-day follow-up 
 
Patients who 
survived  
(n = 462) 
Patients who 
died 
(n = 43) 
p 
Age (years) 82 (77, 85) 83 (80, 86) 0.222 
Female 257 (56) 20 (47) 0.251 
BMI (kg/m2) 26.4 (23.9, 29.8) 26.5 (23.7, 29.8) 0.915 
Logistic EuroSCORE (%) 13.9 (9, 22.2) 19.2 (10.7, 28.9) 0.024 
COPD 100 (22) 11 (26) 0.551 
Extracardiac arteriopathy 115 (25) 9 (21) 0.564 
Recent MI 15 (3) 2 (5) 0.648 
Pulmonary hypertension 91 (20) 8 (19) 0.863 
Coronary artery disease 253 (55) 25 (58) 0.67 
Previous PCI 186 (40) 17 (40) 0.926 
Previous CABG 57 (12) 5 (12) 0.892 
Diabetes mellitus 186 (40) 12 (28) 0.113 
Atrial fibrillation 141 (31) 15 (35) 0.554 
Previous PPM/ ICD  74 (16) 7 (16) 0.964 
Serum creatinine (mg/dl) 1.26 (1.08, 1.59) 1.33 (1.1, 1.71) 0.4 
GFR (ml/min/1.73m2) 49 (39, 60) 47 (34, 59) 0.688 
CKD   0.719 
- No/ Mild CKD 119 (26) 10 (23)  
- Moderate CKD 287 (62) 26 (61)  
- Severe CKD 56 (12) 7 (16)  
Time interval from TTE to TF-
TAVI (days) 
11 (6, 25) 13 (7, 24) 0.356 
LVEF (%) 55 (45, 59) 52 (34, 60) 0.182 
Mean transvalvular aortic gradient 
(mmHg) 
45 (34, 58) 37 (20, 52) 0.004 
Aortic valve area (cm2) 0.7 (0.52, 0.83) 0.74 (0.5, 0.9) 0.362 
Significant mitral regurgitation 204 (44) 17 (40) 0.559 
Significant aortic regurgitation 81 (18) 6 (14) 0.552 
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
BMI = body mass index, CABG = coronary artery bypass surgery, CKD = chronic kidney disease, 
COPD = chronic obstructive pulmonary disease, ICD = implantable cardioverter defibrillator, 
GFR = glomerular filtration rate, LGAS = low gradient aortic stenosis, LVEF = left ventricular 
ejection fraction, MI = myocardial infarction, PCI = percutaneous coronary intervention, PPM 
= permanent pacemaker, TF-TAVI = transfemoral aortic valve implantation, TTE = transthoracic 
echocardiography.  
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Table 11: Baseline characteristics and echocardiographic data of patients who died 
and patients who survived at 1-year follow-up 
 
Patients who 
survived 
(n = 392) 
Patients who 
died 
(n = 113) 
p 
Age (years) 82 (78, 85) 82 (77, 85) 0.821 
Female 227 (58) 50 (44) 0.01 
BMI (kg/m2) 26.5 (24, 29.8) 26.2 (23.4, 29.7) 0.385 
Logistic EuroSCORE (%) 13.8 (9, 22.5) 16.2 (10, 25) 0.126 
COPD 88 (22) 23 (20) 0.636 
Extracardiac arteriopathy 97 (25) 27 (24) 0.853 
Recent MI 9 (2) 8 (7) 0.032 
Pulmonary hypertension 73 (19) 26 (23) 0.301 
Coronary artery disease 211 (54) 67 (59) 0.303 
Previous PCI 152 (39) 51 (45) 0.225 
Previous CABG 50 (13) 12 (11) 0.542 
Diabetes mellitus 153 (39) 45 (40) 0.879 
Atrial fibrillation 116 (30) 40 (35) 0.239 
Previous PPM/ ICD  65 (17) 16 (14) 0.536 
Serum creatinine (mg/dl) 1.25 (1.06, 1.57) 1.37 (1.11, 1.7) 0.052 
GFR (ml/min/1.73m2) 50 (39, 60) 47 (34, 61) 0.445 
CKD   0.322 
- No/ Mild 98 (25) 31 (27)  
- Moderate 249 (63.5) 64 (57)  
- Severe 45 (11.5) 18 (16)  
Time interval from TTE to TF-
TAVI (days) 
12 (5, 26) 12 (6, 23) 0.823 
LVEF (%) 55 (45, 59) 52 (37, 58) 0.045 
Mean transvalvular aortic 
gradient (mmHg) 
47 (35, 59) 40 (26, 51) 
< 
0.001 
Aortic valve area (cm2) 0.7 (0.52, 0.82) 0.7 (0.56, 0.9) 0.385 
Significant mitral regurgitation 173 (44) 48 (43) 0.755 
Significant aortic regurgitation 71 (18) 16 (14) 0.327 
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
BMI = body mass index, CABG = coronary artery bypass surgery, CKD = chronic 
kidney disease, COPD = chronic obstructive pulmonary disease, ICD = implantable 
cardioverter defibrillator, GFR = glomerular filtration rate, LGAS = low gradient aortic 
stenosis, LVEF = left ventricular ejection fraction, MI = myocardial infarction, PCI = 
percutaneous coronary intervention, PPM = permanent pacemaker, TF-TAVI = 
transfemoral aortic valve implantation, TTE = transthoracic echocardiography.  
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3.5.2. Mortality in the different categories of baseline left ventricular ejection fraction 
All-cause mortality at 30 days after TF-TAVI was 7.1% in patients with a normal LVEF (20 
of 280 patients), 6.6% in patients with a mildly abnormal LVEF (8 of 121 patients), 13.5% 
in patients with a moderately abnormal LVEF and 16.7% in patients with a severely 
abnormal LVEF (5 of 30 patients). One-year mortality was 20% in patients with a normal 
LVEF (56 of 280 patients), 19.8% in patients with a mildly abnormal LVEF (24 of 121 
patients), 28.4% in patients with a moderately abnormal LVEF (20 of 74 patients) and 40% 
in patients with a severely abnormal LVEF (12 of 30 patients).  
There was, however, no difference in all-cause mortality between patients with a normal and 
a mildly abnormal LVEF at 30-day and 1-year follow-up. Likewise, there was no significant 
difference in all-cause mortality between patients with a moderately and a severely abnormal 
LVEF (figure 2, panel a). When combining the patients with a normal and a mildly 
abnormal LVEF in one group and the patients with a moderately and a severely abnormal 
LVEF in another group, both, 30-day (14.4% versus 7%, p = 0.017) and 1-year mortality 
(31.7% versus 20%, p=0.007) were significantly higher in the latter group (figure 2, panel 
b). Further baseline and echocardiographic characteristics of these two patient groups are 
summarized in table 12. 
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(a) All-cause mortality in all four categories of LVEF 
 
 
 
(b) All-cause mortality in patients with a normal or mildly abnormal LVEF and patients 
with a moderately or severely abnormal LVEF 
 
Figure 2: Mortality in different categories of baseline ejection fraction 
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Table 12: Comparison of patients with normal or mildly abnormal ejection fraction 
and patients with moderately or severely abnormal ejection fraction 
 
LVEF 
Normal or 
mildly 
abnormal  
(n = 401) 
Moderately or 
severely 
abnormal  
(n = 104) 
p 
Age (years) 82 (78, 85) 81 (76.5, 84) 0.113 
Female 239 (60) 38 (36.5) < 0.001 
BMI (kg/m2) 26.4 (24, 29.7) 26.4 (23.9, 30.9) 0.912 
Logistic EuroSCORE (%) 12.8 (8.4, 19.1) 25.3 (14.6, 32) < 0.001 
COPD 91 (23) 20 (19) 0.447 
Extracardiac arteriopathy 88 (22) 36 (35) 0.007 
Recent MI 10 (2.5) 7 (7) 0.059 
Pulmonary hypertension 73 (18) 26 (25) 0.12 
Coronary artery disease 205 (51) 73 (70) < 0.001 
Previous PCI 153 (38) 50 (48) 0.066 
Previous CABG 42 (10.5) 20 (19) 0.015 
Diabetes mellitus 151 (38) 47 (45) 0.161 
Atrial fibrillation 117 (29) 39 (37.5) 0.102 
Previous PPM/ ICD  50 (12.5) 31 (30) < 0.001 
Serum creatinine (mg/dl) 1.24 (1.04, 1.57) 1.39 (1.19, 1.89) < 0.001 
GFR (ml/min/1.73m2) 50 (39. 60) 46 (34, 56) 0.014 
CKD   0.028 
- No/ Mild 111 (28) 18 (17) 0.031 
- Moderate 246 (61) 67 (65) 0.565 
- Severe 44 (11) 19 (18) 0.045 
Time interval from TTE to TF-TAVI 
(days) 
11 (6, 25) 14 (6, 29) 0.154 
LVEF (%) 56 (51, 61) 33 (28, 37) _ 
Mean transvalvular aortic gradient 
(mmHg) 
48 (36, 61) 34 (21, 46) < 0.001 
Aortic valve area (cm2) 0.7 (0.57, 0.85) 0.65 (0.5, 0.8) 0.037 
LGAS 125 (31) 67 (64) < 0.001 
Significant mitral regurgitation 160 (40) 61 (59) 0.001 
Significant aortic regurgitation 73 (18) 14 (13.5) 0.254 
Data are presented as count (percentage) or median (25th percentile, 75th percentile) 
BMI = body mass index, CABG = coronary artery bypass surgery, CKD = chronic kidney 
disease, COPD = chronic obstructive pulmonary disease, ICD = implantable cardioverter 
defibrillator, GFR = glomerular filtration rate, LGAS = low gradient aortic stenosis, 
LVEF = left ventricular ejection fraction, MI = myocardial infarction, PCI = 
percutaneous coronary intervention, PPM = permanent pacemaker, TF-TAVI = 
transfemoral aortic valve implantation, TTE = transthoracic echocardiography.  
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3.5.3. Mortality in patients with and without low gradient aortic stenosis 
The presence of LGAS was associated with both an increased 30-day (12.5% in patients with 
LGAS versus 6.1% in patients without LGAS, p = 0.011) and an increased 1-year mortality 
(27.6% in patients with LGAS versus 19.2% in patients without LGAS, p = 0.017) (figure 
3). 
 
 
Figure 3: Mortality in patients with and without low gradient aortic stenosis 
3.5.4. Mortality in patients with low gradient aortic stenosis according to baseline 
ejection fraction 
Both 30-day and 1-year mortality in patients with LGAS were similar compared to those 
without LGAS in the groups with a normal baseline LVEF (7.9% versus 6.8% at 30 days, p 
= 0.728 and 21.3% versus 19.4% at one year, p = 0.653) and a mildly abnormal LVEF (8.3% 
versus 5.9% at 30 days, p = 0.609 and 19.4% versus 20% at one year, p = 0.986). They were 
higher compared to those without LGAS in the groups with a moderately abnormal LVEF 
(20.5% versus 3.3% at 30 days, p = 0.038 and 38.6% versus 13.3% at one year, p = 0.019) 
and a severely abnormal LVEF (21.7% versus 0 at 30 days, p = 0.196 and 43.4% versus 
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28.6% at one year, p = 0.399), albeit the difference was not statistically significant in the 
latter group, most likely due to the low number of patients (figure 4).  
 
(a) All-cause mortality in patients with and without LGAS and a normal LVEF 
 
 
(b) All-cause mortality in patients with and without LGAS and a mildly abnormal LVEF 
 
 
Figure 4: Mortality in patients with low gradient aortic stenosis according to 
baseline left ventricular ejection fraction 
 
 
 44 
 
 
 
(c) All-cause mortality in patients with and without LGAS and a moderately 
abnormal LVEF 
 
 
(d) All-cause mortality in patients with and without LGAS and a severely abnormal 
LVEF 
 
Figure 4 (continued): Mortality in patients with low gradient aortic stenosis 
according to baseline left ventricular ejection fraction 
 
 
For further assessment of the impact of LGAS on mortality, patients with a normal and a 
mildly abnormal LVEF were again combined in one group and patients with a moderately 
and severely abnormal LVEF were combined in another group (see 3.5.2). Consequently, 
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the following four groups were analyzed regarding 30-day and 1-year all-cause mortality: 
patients with a moderately or severely abnormal LVEF and LGAS (n = 67), patients with a 
moderately or severely abnormal LVEF without LGAS (n = 37), patients with a normal or 
mildly abnormal LVEF and LGAS (n = 125) and patients with a normal or mildly abnormal 
LVEF without LGAS (n = 276). Patients with a moderately or severely abnormal LVEF and 
LGAS showed an increased mortality at 30 days (20.9% versus 2.7% / 8% / 6.5%, p = 0.001) 
and at one year after TF-TAVI (40.3% versus 16.2% / 20.8% / 19.6%, p = 0.001) compared 
to the other groups (figure 5). 
 
Figure 5: All-cause mortality in patients with normal or mildly abnormal left 
ventricular ejection fraction and patients with moderately or severely abnormal left 
ventricular ejection fraction in the presence and absence of low gradient aortic 
stenosis 
3.5.5. Predictors of thirty-day and one-year mortality  
A moderately or severely abnormal LVEF (hazard ratio 2.112, 95% confidence interval 
1.128 to 3.955, p = 0.019) and a LGAS (hazard ratio 2.132, 95% confidence interval 1.168 
to 3.893, p = 0.014) were identified as predictors of 30-day mortality in the univariate Cox 
regression analysis (table 13). 
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      Table 13: Univariate Cox regression analysis of thirty-day mortality 
 B SE HR 95% Confidence interval p 
Age 0.018 0.027 1.019 0.967 to 1.073 0.492 
Female -0.34 0.306 0.712 0.391 to 1.296 0.266 
Logistic EuroSCORE 0.019 0.01 1.019 0.999 to 1.039 0.06 
Extracardiac arteriopathy -0.205 0.375 0.814 0.391 to 1.698 0.814 
Recent myocardial infarction 0.343 0.724 1.41 0.341 to 5.827 0.635 
Pulmonary hypertension -0.065 0.392 0.937 0.435 to 2.021 0.869 
Coronary artery disease 0.132 0.309 1.141 0.623 to 2.092 0.669 
Previous CABG -0.066 0.472 0.936 0.369 to 2.379 0.89 
Previous PPM/ ICD  0.008 0.413 1.008 0.448 to 2.265 0.985 
Atrial fibrillation 0.19 0.32 1.21 0.646 to 2.265 0.552 
CKD  
- No/ mild _ _ _ _ _ 
- Moderate 0.073 0.372 1.076 0.519 to 2.231 0.884 
- Severe 0.38 0.493 1.462 0.557 to 3.842 0.441 
COPD 0.192 0.35 1.211 0.61 to 2.403 0.584 
Diabetes mellitus -0.521 0.34 0.594 0.305 to 1.157 0.126 
Moderately/ severely abnormal LVEF 0.748 0.32 2.112 1.128 to 3.955 0.019 
LGAS 0.757 0.307 2.132 1.168 to 3.893 0.014 
Aortic valve area 0.824 0.591 2.28 0.715 to 7.268 0.163 
Significant mitral regurgitation 0.172 0.312 1.188 0.645 to 2.189 0.581 
TF-TAVI with a self-expandable prosthesis 0.24 0.361 1.271 0.626 to 2.578 0.507 
B = B coefficient, SE = Standard error, HR = Hazard ratio 
CABG = coronary artery bypass surgery, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, 
ICD = implantable cardioverter defibrillator, LGAS = low gradient aortic stenosis, LVEF = left ventricular ejection fraction, 
PPM = permanent pacemaker, TF-TAVI = transfemoral aortic valve implantation.  
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The only predictor of 30-day mortality in the multivariate analysis, which included LVEF, 
LGAS, aortic valve area, logistic EuroSCORE and diabetes mellitus, was LGAS (hazard 
ratio 2.132, 95% confidence interval 1.168 to 3.893, p = 0.014). After introduction of the 
predefined interaction term (LVEF*LGAS), the only predictor of an increased 30-day 
mortality was the co-existence of a moderately or severely abnormal LVEF and a LGAS 
(hazard ratio 3.33, 95% confidence interval 1.759 to 6.303, p < 0.001). 
At 1-year follow-up, a moderately or severely abnormal LVEF (hazard ratio 1.732, 95% 
confidence interval 1.154 to 2.598, p = 0.008), a LGAS (hazard ratio 1.559, 95% confidence 
interval 1.077 to 2.256, p = 0.019), recent myocardial infarction (hazard ratio 2.378, 95% 
confidence interval 1.159 to 4.881, p = 0.018) and female gender (hazard ratio 0.621, 95% 
confidence interval 0.428 to 0.9, p = 0.012) were predictors of mortality in the univariate 
analysis (table 14). In the multivariate analysis that included LVEF, LGAS, recent 
myocardial infarction and gender, only a moderately or severely abnormal LVEF (hazard 
ratio 1.664, 95% confidence interval 1.105 to 2.504, p=0.015) and recent myocardial 
infarction (hazard ratio 2.137, 95% confidence interval 1.035 to 4.143, p=0.04) predicted 1-
year mortality after TF-TAVI. When the prespecified interaction term of 
moderately/severely abnormal LVEF and LGAS was introduced to this model, the 
interaction between a moderately/severely abnormal LVEF and LGAS was the only 
independent predictor of increased 1-year mortality after TF-TAVI (hazard ratio 2.415, 95% 
confidence interval 1.566 to 3.722, p < 0.001). 
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Table 14: Univariate Cox regression analysis of one-year mortality 
 B SE HR 95% Confidence interval p 
Age -0.009 0.016 0.991 0.961 to 1.022 0.573 
Female -0.476 0.189 0.621 0.428 to 0.9 0.012 
Logistic Euroscore 0.009 0.007 1.009 0.995 to 1.023 0.216 
Extracardiac arteriopathy -0.032 0.221 0.969 0.629 to 1.493 0.886 
Recent myocardial infarction 0.866 0.367 2.378 1.159 to 4.881 0.018 
Pulmonary hypertension 0.218 0.224 1.243 0.802 to 1.927 0.33 
Coronary artery disease 0.19 0.191 1.21 0.831 to 1.761 0.32 
Previous CABG -0.173 0.305 0.841 0.462 to 1.53 0.57 
Previous PPM/ ICD implantation -0.166 0.27 0.847 0.499 to 1.438 0.539 
Atrial fibrillation 0.226 0.197 1.253 0.852 to 1.842 0.257 
CKD  
- No/ mild _ _ _ _ _ 
- Moderate 0.148 0.219 1.16 0.755 to 1.781 0.498 
- Severe 0.215 0.296 1.24 0.694 to 2.216 0.468 
COPD -0.101 0.234 0.904 0.572 to 1.429 0.665 
Diabetes mellitus 0.008 0.192 1.008 0.692 to 1.469 0.966 
Moderately/ severely abnormal LVEF 0.549 0.207 1.732 1.154 to 2.598 0.008 
LGAS 0.444 0.189 1.559 1.077 to 2.256 0.019 
Aortic valve area 0.42 0.388 1.522 0.712 to 3.255 0.279 
Significant mitral regurgitation -0.069 0.19 0.933 0.643 to 1.355 0.717 
TF-TAVI with a self-expandable prosthesis 0.267 0.224 1.306 0.842 to 2.023 0.233 
B = B coefficient, SE = Standard error, HR = Hazard ratio 
CABG = coronary artery bypass surgery, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ICD = 
implantable cardioverter defibrillator, LGAS = low gradient aortic stenosis, LVEF = left ventricular ejection fraction, MI = 
myocardial infarction, PPM = permanent pacemaker, TF-TAVI = transfemoral aortic valve implantation. 
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4. Discussion 
4.1. Findings of the study 
This study aimed to assess the impact of LVEF on the outcome of patients with severe AS 
undergoing TF-TAVI. We found that LVEF was normal in 55%, mildly abnormal in 24%, 
moderately abnormal in 15% and severely abnormal in 6% of the patients, and that 
moderately or severely abnormal LVEF (21% of all patients) was an independent predictor 
of 1-year mortality after TF-TAVI. Patients with a mildly abnormal LVEF had a similar 
outcome compared to patients with a normal LVEF. 
We also aimed to assess the impact of LGAS, a common condition in patients with impaired 
LVEF, on outcome and its possible interaction with LVEF. We found that a LGAS was 
present in 38% of patients and its prevalence varied according to the baseline LVEF. A 
LGAS was detected in nearly one-third of the patients with a normal or mildly abnormal 
LVEF and in two-thirds of the patients with a moderately or severely abnormal LVEF. 
LGAS was an independent predictor of 30-day mortality after TF-TAVI (hazard ratio 2.132). 
The co-existence of a moderately or severely abnormal LVEF and a LGAS (13% of all 
patients) was the strongest predictor of 30-day (hazard ratio 3.33) and 1-year mortality 
(hazard ratio 2.415).  
4.2. Prevalence of abnormal ejection fraction and low gradient aortic stenosis 
Baseline LVEF was mildly abnormal in 24%, moderately abnormal in 15% and severely 
abnormal in 6% of patients in this study. Age was similar between all study groups. The 
baseline characteristics of the patients with a mildly abnormal LVEF were similar to those 
with a normal LVEF except for more frequent implanted permanent pacemaker or 
cardioverter defibrillator devices. Whereas patients with a moderately or severely abnormal 
LVEF (21% of all patients) had more comorbidities than those with a normal or mildly 
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abnormal LVEF, they exhibited a higher prevalence of coronary artery disease, extracardiac 
atherosclerotic vascular disease, CKD, implanted pacemakers or cardioverter defibrillator 
devices and showed male predominance. Their logistic EuroSCORE was higher than that of 
patients with a normal LVEF. These patients had a smaller aortic valve area than patients 
with a normal or mildly abnormal LVEF, which may be related to an increased aortic valve 
calcification due to more advanced vascular and kidney disease. 
A LGAS was present in 38% of all patients and was more common in patients with a 
moderately or severely abnormal LVEF (64%) compared to those with a normal or mildly 
abnormal LVEF (31%).  
Our findings are similar to previously reported data from other studies, although direct 
comparisons are difficult due to different cutoff points used to describe an impairment of 
LVEF. In the German Aortic Valve Registry, severe impairment of LVEF (≤ 30%) was 
present in 12% of 1,432 patients undergoing TAVI. These patients had a higher logistic 
EuroSCORE, increased comorbidities, a higher prevalence of significant mitral regurgitation 
and LGAS compared to patients with a LVEF > 30%. Patients with a severely impaired 
LVEF were also more likely to be males and were younger compared to patients with a 
LVEF > 30% (Schaefer et al. 2015). In the United Kingdom-TAVI registry, the prevalence 
of a severely abnormal LVEF in patients undergoing TAVI was 10% (Ludman et al. 2015) 
and in a multicenter Italian registry patients with a LVEF < 40% represented 20% of the 
whole TAVI population (Tamburino et al. 2011). Clinical data from the Transcatheter Valve 
Therapy Registry, which included 11,292 patients undergoing TAVI, showed that about two-
thirds of patients had a normal LVEF (> 50%), 26% had a LVEF between 30% and 50%, 
and only 8% had a LVEF < 30%. Similar to our patients, those with a severely impaired 
LVEF had more comorbidities, higher risk scores (assessed by the Society of Thoracic 
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Surgeons risk score), significant mitral valve regurgitation and a smaller aortic valve area. 
One-third of these patients had a LGAS (Baron et al. 2016). These examples demonstrate 
that our study population, though coming from a single center, mirrors real world multicenter 
and registry data. In brief, approximately one-fifth of TAVI patients has at least a moderate 
impairment of LVEF and about one-third of all patients has LGAS. 
4.3. Impact of left ventricular ejection fraction on all-cause mortality 
In the univariate analysis, we found that a moderately or severely abnormal baseline LVEF 
is associated with an increased 30-day and 1-year mortality after TF-TAVI. In the 
multivariate analysis, however, a moderately or severely abnormal LVEF was only 
associated with an increased 1-year mortality. The outcome of patients with a mildly 
abnormal LVEF was similar to that of patients with a normal LVEF both at 30 days and one 
year.  
We used the current ASE/EACVI recommendations to assess the grade of the impairment 
of LVEF (Lang et al. 2015), which represent a more detailed approach than the commonly 
used cutoffs to define a normal LVEF as > 50% or a severely impaired LVEF as < 30% 
(Roques et al. 2003, Duncan et al. 2015, Baron et al. 2016). The ASE/EACVI also offered 
different cutoff values for females and males. These appear to be of no prognostic relevance 
in patients undergoing TF-TAVI compared to the 50% cutoff value for a normal LVEF for 
both genders as endorsed by the current guidelines for the management of valvular heart 
disease (Baumgartner et al. 2017). However, patients with a mildly abnormal LVEF could 
be identified as a subgroup of patients with an impaired LVEF that showed similar baseline 
characteristics and outcomes both at 30 days and at one year compared to patients with a 
normal LVEF. 
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The association between the baseline LVEF and the outcome after TAVI was previously 
reported in observational studies, in national TAVI registries as well as in meta-analyses. 
The results of these different studies are conflicting. Many investigators found a predictive 
value for an impaired LVEF on outcome after TAVI. Analysis of the clinical data from the 
German Aortic Valve Registry revealed that a baseline LVEF  30% is a predictor of an 
increased 30-day and 1-year mortality. In this registry, patients were classified into two 
groups based on their baseline LVEF with a cutoff value of 30%. TF-TAVI was the most 
frequently used access in both groups (88.8% vs 87.6%, p = 0.46) with the Medtronic 
CoreValve being the most commonly implanted prosthesis. Both groups of patients showed 
comparable improvement of their functional status, while both 30-day and 1-year mortality 
were significantly higher in patients with a LVEF  30% (Schaefer et al. 2015). Similar 
findings were detected in the United Kingdom-TAVI Registry that enrolled 870 patients. In 
that registry, a LVEF < 30% was a predictor of increased 1-year mortality (hazard ratio 1.65, 
p= 0.06) (Moat et al. 2011), whereas LVEF values between 30% to 49% and LVEF values 
< 30% were both independent predictors of mortality at longer term follow-up (Duncan et 
al. 2015). Likewise, in a retrospective two-center study from Italy with 384 patients, 
investigators found a three-fold higher 30-day and a two-fold higher 1-year mortality in 
patients with a LVEF ≤ 35% compared to patients with a LVEF > 35%. The majority of 
patients (75%) were treated using the transfemoral approach. Patients with a LVEF ≤ 35% 
were younger, had more comorbidities, and a higher logistic EuroSCORE compared to those 
with a LVEF > 35% (Fraccaro et al. 2012). Similarly, Elhmidi et al. showed that patients 
with a LVEF < 35% had a two-fold higher mortality at six months compared to patients with 
a normal LVEF (> 50%) (Elhmidi et al. 2014). In another study, a baseline LVEF ≤ 40% 
predicted death from heart failure in patients undergoing TAVI and was associated with 
higher risk of sudden cardiac death (Urena et al. 2015). In the France-2 Registry that enrolled 
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3,933 consecutive TAVI patients, an impaired LVEF (< 50%) was an independent predictor 
of 1-year mortality after TAVI (Amabile et al. 2014).  
In addition to these studies, two recent meta-analyses showed that any degree of impairment 
of LVEF is associated with an increased 1-year mortality after TAVI. Eleid et al. included 
16 observational studies published between 2010 and 2014 in a meta-analysis on the impact 
of a reduced stroke volume index, a low mean transvalvular aortic gradient and a reduced 
LVEF on 1-year all-cause mortality after TAVI. The meta-analysis comprised 7,673 
patients. Data of all patients were included in the LVEF analysis, while data of 3,790 patients 
were available for the low mean transvalvular aortic gradient analysis and only data of 2,032 
patients for the stroke volume index analysis. They found that these three parameters are all 
associated with an increased 1-year mortality after TAVI (Eleid et al. 2015). Luo et al. 
analyzed data from 28 studies comprising 14,099 patients to determine the association 
between an impaired LVEF and the prognosis of patients after TAVI. While an impaired 
LVEF was not related to 30-day mortality, it was related to midterm mortality at one and 
two years (Luo et al. 2015). 
In contrast to these findings, other investigators did not find that an impaired LVEF had an 
impact on mortality in patients with severe AS undergoing TAVI. In a single center registry, 
clinical outcomes of high risk patients with severe AS undergoing medical treatment (n= 71) 
or TAVI (n= 256) stratified by LVEF with a cutoff point of 30% were compared. Twenty-
five patients (35%) among the medical cohort and 37 patients (14%) among the TAVI cohort 
had a LVEF ≤ 30%. During follow-up of 2.5 years, patients undergoing TAVI had similar 
mortality rates irrespective of their baseline LVEF, whereas mortality was markedly 
increased in patients with a LVEF ≤ 30% who were treated medically (Pilgrim et al. 2011). 
Likewise, a multicenter retrospective Italian study included 649 patients to assess the impact 
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of a reduced baseline LVEF on both short and mid-term mortality after TAVI. A cutoff value 
of 30% was used to indicate severe impairment of the LVEF. Although patients with a LVEF 
of ≤ 30% had a higher EuroSCORE and a higher New York Heart Association functional 
class compared to those with a LVEF > 30%, all cause and cardiac mortality were similar in 
both patient groups (Ferrante et al. 2016). In a multicenter registry including 663 patients 
undergoing TAVI using the self-expandable CoreValve prosthesis, LVEF < 40% was a 
predictor of 30-day mortality but not 1-year mortality (Tamburino et al. 2011). Likewise, 
patients with a LVEF ≤ 45% had similar in-hospital and 1-year outcomes after TAVI 
compared to patients with a LVEF > 45% in a single center study comprising 371 
consecutive patients. One-year mortality was 22% in both groups (Barbash et al. 2014). A 
recent analysis of the data of all TAVI procedures performed in the United Kingdom (3,980 
patients from 2007 to 2012) concluded that comorbidities such as atrial fibrillation, chronic 
obstructive pulmonary disease, creatinine > 200 micromol/l, diabetes mellitus and coronary 
artery disease were predictors of long-term mortality. A moderately impaired LVEF (defined 
as LVEF values between 30% and 49%) was a predictor of 30-day mortality in the univariate 
but not the multivariate analysis (Ludman et al. 2015). Baron et al. analyzed data of the 
Transcatheter Valve Therapy Registry to assess the impact of an impaired LVEF and a low 
mean transvalvular aortic gradient on clinical outcomes after TAVI. Patients were divided 
into three groups based on their LVEF with the cutoff points < 30% and > 50%.  Severe 
impairment of LVEF was associated with higher rates of mortality (29.3% versus 25.5% 
versus 21.9%, p < 0.001) at 1-year follow-up. Nevertheless, LVEF was not an independent 
predictor of mortality in the multivariate analysis, where it was analyzed as a continuous 
rather than a categorical variable (Baron et al. 2016).  
These different results between studies are multifactorial. First, the cutoff point for an 
abnormal LVEF differs considerably between the various studies. Second, different 
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statistical models were used in various studies: while two recently reported registries 
analyzed LVEF as a continuous variable and found that LVEF had no effect on outcome 
after TAVI (Baron et al. 2016, Kataoka et al. 2017), other registries categorized patients into 
normal and impaired LVEF and found an independent prognostic impact of the LVEF on 
all-cause mortality (Amabile et al. 2014, Schaefer et al. 2015). Third, most of the studies 
included transfemoral and non-transfemoral procedures in the same analysis. This may 
constitute a confounder that masked the impact of baseline LVEF on mortality. On the one 
hand patients with a severely abnormal LVEF undergo transapical TAVI less frequently than 
those with a preserved LVEF (Baron et al. 2016), but on the other hand the outcomes of TF-
TAVI are consistently better than those of transapical TAVI (Thomas et al. 2011, Di Mario 
et al. 2013, Blackman et al. 2014, van der Boon et al. 2014).  
4.4. Impact of low gradient aortic stenosis on all-cause mortality 
In our study, presence of a LGAS was associated with an increased 30-day mortality in the 
multivariate analysis. At 1-year follow-up, LGAS predicted an increased mortality in the 
univariate analysis but not in the multivariate analysis. In the multivariate analysis, only 
baseline LVEF and recent myocardial infarction were independent predictors of increased 
1-year mortality.  
Previous studies showed that a LGAS is associated with poorer long-term outcome after 
TAVI (Zahn et al. 2013, Amabile et al. 2014, Baron et al. 2016). The 1-year follow-up of 
the German Aortic Valve Registry, in which the clinical data of 1,318 consecutive patients 
were reviewed, showed that a LGAS was an independent predictor of 1-year mortality 
(hazard ratio 1.83, 95% confidence interval 1.29 to 2.61) as well as previous myocardial 
infarction (hazard ratio 1.48, 95% confidence interval 1.08 to 2.03). However, baseline 
LVEF was not included in the analysis (Zahn et al. 2013). In the France-2 Registry, LGAS 
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was present in 23.5% of patients and was associated with an increased 1-year mortality after 
TAVI (hazard ratio 1.53, 95% confidence interval 1.15 to 2.04). Impaired LVEF (< 50%) 
was also an independent predictor of mortality (hazard ratio 1.66, 95% confidence interval 
1.23 to 2.27) (Amabile et al. 2014).  Likewise, LGAS was an independent predictor of 1-
year mortality (hazard ratio 1.21, 95% confidence interval 1.11 to 1.32) in the Transcatheter 
Valve Therapy Registry (Baron et al. 2016).  
Our results should not be interpreted as being contradictory with these findings. We found 
that LGAS and a moderate or severe impairment of LVEF for themselves were predictors of 
1-year mortality in the univariate analysis. Indeed, the unadjusted hazard ratio for LGAS in 
our univariate analysis (1.559) was similar to the unadjusted hazard ratio in the France-2 
Registry (1.6) (Amabile et al. 2014). The different results of the multivariate analysis in our 
study compared to others may be explained by a larger number of patients in the nationwide 
registries (Zahn et al. 2013, Amabile et al. 2014, Baron et al. 2016) and methodological 
differences in study design (Zahn et al. 2013, Baron et al. 2016). Yet, the combination of 
LGAS and a moderately or severely abnormal LVEF was an independent predictor of both 
30-day and 1-year mortality (see below). 
4.5. Impact of ejection fraction and low gradient aortic stenosis on all-cause mortality 
We found that patients with a moderately or severely abnormal LVEF were at increased risk 
of 30-day and 1-year mortality in the presence of a LGAS. Patients with a moderately or 
severely abnormal LVEF who did not have a LGAS had a comparable outcome to patients 
with a normal or mildly abnormal LVEF. 
Several recent studies investigated the additive prognostic value of LGAS and LVEF in 
patients undergoing TAVI. In a single center study, 202 consecutive patients undergoing 
TAVI with the self-expandable CoreValve prosthesis were divided into four groups 
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according to LVEF (> 50% versus ≤ 50%) and mean transvalvular aortic gradient (> 40 
mmHg versus ≤ 40 mmHg) and followed up for one year. Overall, 1-year mortality was 23% 
and was highest in the group of patients with an impaired LVEF and a low gradient (39%) 
(Gotzmann et al. 2012). Researchers from a multicenter observational study in Italy 
investigated the effect of LVEF and mean transvalvular aortic gradients on the outcome after 
TAVI analyzing data of 764 consecutive patients. They assigned the cutoff point of 40% for 
a preserved versus an impaired LVEF and found that the combination of LGAS with a LVEF 
< 40% was a predictor of increased mortality (hazard ratio 2.4) at a median follow-up of 396 
days (Conrotto et al. 2017). Two single center studies from Germany demonstrated similar 
findings. Schewel et al. found that patients with a severely impaired LVEF (≤ 30%) and a 
LGAS had an increased 30-day and 1-year mortality. One-year mortality in these patients 
was 38.2% compared to 11.4% in patients with a normal LVEF (> 50%) and a high mean 
transvalvular aortic gradient  (Schewel et al. 2016). Puls et al. analyzed the data of 400 
consecutive TAVI patients. They classified the enrolled patients according to baseline LVEF 
and mean transvalvular aortic gradient to study their impact on long-term outcome. One-
hundred-and-forty-seven patients had a normal LVEF (≥ 50%) and a high mean transvalvular 
aortic gradient (≥ 40 mmHg), 63 patients had an impaired LVEF and high mean transvalvular 
aortic gradient, 77 patients had a normal LVEF and a low mean transvalvular aortic gradient, 
and 81 patients had an impaired LVEF and a low mean transvalvular artic gradient. The 
overall 1-year mortality was 26% with the highest rate of death in the group of patients with 
an impaired LVEF and a low mean transvalvular aortic gradient (43% versus 14% in the 
group with a normal LVEF and a high mean transvalvular aortic gradient). Multivariate 
analysis showed that the combined status of an impaired LVEF and a low mean transvalvular 
aortic gradient predicted both all-cause and cardiovascular mortality after TAVI (Puls et al. 
2017). Likewise, analysis of data from national TAVI registries showed similar findings. 
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Patients with a LGAS and an impaired LVEF (< 40%) in the German Aortic Valve Registry 
had a higher in-hospital and 1-year mortality than those with LGAS and a normal LVEF (> 
50%). In contrast, the outcome of patients with LGAS and a normal LVEF was comparable 
to those with a high mean transvalvular aortic gradient (Lauten et al. 2014). In the United 
Kingdom-TAVI registry, an abnormal LVEF (< 50%) was associated with an increased 
mortality at 2-year follow-up only in patients with a low transvalvular aortic gradient 
(defined as a peak gradient < 64 mmHg). In the group of patients with a normal LVEF, there 
was no difference in mortality between patients with low transvalvular aortic gradients and 
those with high gradients (Malkin et al. 2016). 
The prognostic impact of the co-existence of an impaired LVEF with LGAS seems to be 
consistent between studies. All-cause mortality of the patients with a LVEF < 40% and 
LGAS in two previous studies was 40.6% at median follow-up of 396 days (Conrotto et al. 
2017) and 43% at 1-year follow-up (Puls et al. 2017). This is similar to the 1-year all-cause 
mortality rate (40.3%) in patients with a moderately or severely abnormal LVEF and 
coexisting LGAS in our study. 
In contrast to these findings O’Sullivan et al. found no differences in 30-day or 1-year all-
cause mortality between patients with combined LGAS and an impaired LVEF (< 50%) and 
those with a normal LVEF after TAVI in a retrospective single center study (O'Sullivan et 
al. 2013). Baron et al. found that LGAS, but not an impaired LVEF, was predictive of 1-year 
mortality. They found no interaction between LVEF (as a continuous variable) and LGAS 
on outcome. Nevertheless, the highest 1-year mortality in their study was found in the group 
of patients with a severely abnormal LVEF and LGAS (33%) and the lowest 1-year mortality 
was found in patients with a normal LVEF and a high mean transvalvular aortic gradient 
(21%) (Baron et al. 2016). 
 59 
 
Overall, the coexistence of a moderately or severely abnormal LVEF and LGAS increases 
30-day and 1-year mortality after TF-TAVI. When either LVEF is preserved or the mean 
transvalvular aortic gradient is high in the setting of severe AS, the outcome appears to be 
favorable due to the presence of a contractile reserve of the left ventricular myocardium or 
the absence of significant myocardial fibrosis (Herrmann et al. 2011). The proportion of 
patients with at least a moderately abnormal LVEF and a LGAS undergoing TAVI is 
considerably low and accounts for 13% of all patients in our study and for 8.4% to 22.5% of 
all patients in previous reports (Debry et al. 2016, Malkin et al. 2016, Schewel et al. 2016, 
Conrotto et al. 2017). This patient cohort is at high risk for an adverse outcome after TAVI 
and may, thus, deserve further testing in the decision making process in order to better 
stratify the individual risk of a TAVI procedure (Hayek et al. 2015). After careful revision 
of all available clinical data and confirmation of the presence of severe AS, TF-TAVI in 
these patients still should be strongly considered given the dismal prognosis if treated 
conservatively (Baumgartner et al. 2017). 
4.6. Clinical implications 
This study shows that the co-existence of a moderately or severely abnormal LVEF and a 
LGAS identifies a group of patients with an increased mortality after TF-TAVI. Yet, the 
procedural outcome remains favorable when either the LVEF is preserved or the mean 
transvalvular aortic gradient is high, as already proposed in the current guidelines for the 
management of valvular heart disease (Baumgartner et al. 2017). Furthermore, we showed 
that a mildly abnormal LVEF is not associated with an increased mortality after TF-TAVI, 
irrespective of the mean transvalvular aortic gradient. Accordingly, risk stratification of 
patients with mildly abnormal LVEF, especially if accompanied with LGAS, should follow 
the pathway of patients with a normal LVEF, since these patients still have a favorable 
prognosis after TF-TAVI. Though the co-existence of a moderately or severely abnormal 
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LVEF and a LGAS identifies patients with an increased mortality after TF-TAVI, their 
outcome is still better than medical therapy alone. TF-TAVI may improve the prognosis in 
this very high risk group but further studies are needed to define outcome predictors after 
TF-TAVI in these patients. 
4.7. Limitations 
Our study has certain limitations including the inherent limitations of observational reports. 
In addition, we did not include flow state across the stenotic aortic valve in our analysis, 
since the required data were not routinely documented in the TTE reports. Only all-cause 
mortality was reported in this study and not cardiovascular mortality, as the exact cause of 
death was not known to us for every patient. Stress echocardiography was not performed in 
patients who had both an abnormal LVEF and LGAS for further risk stratification. Follow-
up TTE data that might detect an improvement of LVEF after TAVI were not collected. 
Thus, recovery of the LVEF was not evaluated as part of our study. Nevertheless, no loss of 
patients at follow-up, direct access to baseline TTE data, adherence to ASE/EACVI 
recommendations for the classification of LVEF impairment and including only TF-TAVI 
patients in this analysis are remarkable strengths of this study. 
5. Conclusion 
A moderately or severely abnormal LVEF at baseline is associated with increased mortality 
after TF-TAVI when the mean transaortic gradient is less than 40 mmHg, while outcomes 
in patients with a normal and mildly abnormal LVEF are comparable regardless the pressure 
gradient across the aortic valve.  
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6. Summary 
Data on the impact of baseline left ventricular ejection fraction (LVEF) on outcome after 
transcatheter aortic valve implantation (TAVI) are inconsistent, and there is a potential 
confounding effect of a low transvalvular aortic gradient (< 40 mmHg = LGAS). Moreover, 
the cutoff points to define an impaired LVEF in previous TAVI studies are rather arbitrary. 
We, therefore, studied the impact of the recommendations of the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging for 
classification of an impaired LVEF on the 30-day and 1-year mortality in patients with 
severe symptomatic aortic stenosis who underwent transfemoral (TF-) TAVI. The impact of 
a LGAS was also evaluated. 
Baseline LVEF was normal in 280 (55%), mildly abnormal in 121 (24%), moderately 
abnormal in 74 (15%) and severely abnormal in 30 (6%) patients, respectively. Thirty-day 
and 1-year mortality were 8.5% and 22.4%, respectively, and patients with a normal or 
mildly abnormal LVEF (> 40%) had similar outcomes. However, mortality was increased in 
patients with a moderately or severely abnormal LVEF (≤ 40%), especially in the presence 
of LGAS. Patients with a moderately or severely abnormal LVEF and a LGAS exhibited 
nearly a 2-fold higher 1-year mortality (40.3%) compared to any other patient subgroup. In 
the multivariate analysis, the combination of a moderately or severely abnormal LVEF and 
a LGAS predicted an increased 30-day (hazard ratio 3.33, 95% CI 1.76 to 6.3) and 1-year 
mortality (hazard ratio 2.42, 95% CI 1.57 to 3.72).  
We concluded that a moderately or severely abnormal LVEF at baseline is associated with 
an increased mortality after TF-TAVI when the mean transvalvular aortic gradient is less 
than 40 mmHg, while outcomes in patients with a normal and mildly abnormal LVEF are 
comparable regardless the transvalvular aortic gradient.   
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